Immunohistochemical Biomarkers as a Surrogate of Molecular Analysis in Ovarian Carcinomas: A Review of the Literature

Citations Over TimeTop 10% of 2021 papers

Abstract

The term "ovarian carcinoma" encompasses at least five different malignant neoplasms: high-grade serous carcinoma, low-grade serous carcinoma, endometrioid carcinoma, mucinous carcinoma, and clear cell carcinoma. These five histotypes demonstrated distinctive histological, molecular, and clinical features. The rise of novel target therapies and of a tailored oncological approach has demanded an integrated multidisciplinary approach in the setting of ovarian carcinoma. The need to implement a molecular-based classification in the worldwide diagnostic and therapeutic setting of ovarian cancer demanded a search for easy-to-use and cost-effective molecular-surrogate biomarkers, relying particularly on immunohistochemical analysis. The present review focuses on the role of immunohistochemistry as a surrogate of molecular analysis in the everyday diagnostic approach to ovarian carcinomas.

Related Papers

• → Prognostic Values of Transforming Growth Factor‐Beta Subtypes in Ovarian Cancer(2020)16 cited
• → Radioimmunoscintigraphy of Ovarian Tumours with Tc-99m Labelled Monoclonal Antibody-170(1995)1 cited
• [Betaglucuronidase activity in ovarian carcinoma (author's transl)].(1979)
• [Expression of EVEC in ovarian carcinoma and its biological significance].(2010)
• → On the Validity of Simultaneous Determinations of CA 125, SRA, and CA 72-4 in Patients Suffering from Ovarian Tumors(1993)1 cited